4558
CHUKYO IYAKUHIN CO.,LTD.
中京医薬品
- Industry
- Pharmaceutical
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
5,827,026
Mar 2022
5,356,255
Mar 2023
5,692,647
Mar 2024
6,124,622
Mar 2025
6,306,646
Operating profit(thousand JPY)
Mar 2021
225,575
Mar 2022
64,313
Mar 2023
59,683
Mar 2024
128,271
Mar 2025
106,030
Operating profit margin(%)
Mar 2021
3.87
Mar 2022
1.2
Mar 2023
1.05
Mar 2024
2.09
Mar 2025
1.68
Profit before tax(thousand JPY)
Mar 2021
204,053
Mar 2022
94,485
Mar 2023
77,367
Mar 2024
20,252
Mar 2025
125,786
Profit(thousand JPY)
Mar 2021
94,568
Mar 2022
33,218
Mar 2023
14,487
Mar 2024
-27,318
Mar 2025
45,148
Total assets(thousand JPY)
Mar 2021
5,172,576
Mar 2022
5,339,285
Mar 2023
5,242,712
Mar 2024
5,082,784
Mar 2025
5,065,254
Cash and cash equivalents(thousand JPY)
Mar 2021
1,242,485
Mar 2022
1,286,092
Mar 2023
944,896
Mar 2024
949,434
Mar 2025
1,077,466
Cash flows from operating activities(thousand JPY)
Mar 2021
344,047
Mar 2022
-222,679
Mar 2023
105,833
Mar 2024
171,853
Mar 2025
31,708
Cash flows from investing activities(thousand JPY)
Mar 2021
78,805
Mar 2022
10,501
Mar 2023
-199,959
Mar 2024
-36,046
Mar 2025
53,355
Cash flows from financing activities(thousand JPY)
Mar 2021
369,163
Mar 2022
255,784
Mar 2023
-247,069
Mar 2024
-131,269
Mar 2025
42,967
Return on equity(%)
Mar 2021
4.46
Mar 2022
1.31
Mar 2023
0.56
Mar 2024
-1.07
Mar 2025
1.79
Equity ratio(%)
Mar 2021
47.3
Mar 2022
49
Mar 2023
49.3
Mar 2024
49.6
Mar 2025
49.9
Earnings per share(JPY per share)
Mar 2021
10.51
Mar 2022
3.16
Mar 2023
1.36
Mar 2024
-2.57
Mar 2025
4.24
Net assets per share(JPY per share)
Mar 2021
242.35
Mar 2022
246.38
Mar 2023
242.89
Mar 2024
236.95
Mar 2025
236.98
Dividend per share(JPY per share)
Mar 2021
7
Mar 2022
5
Mar 2023
5
Mar 2024
5
Mar 2025
5
Payout ratio(%)
Mar 2021
66.6
Mar 2022
158.23
Mar 2023
367.65
Mar 2024
-
Mar 2025
117.92
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.